Dima Shulkin: A Novel Monocyte-Based Biomarker of Cardiovascular Risk
Dima Shulkin, Co-Founder and CTO at RobotDreams GmbH, shared a post on LinkedIn:
“What if a simple blood test could flag hidden heart disease long before any symptoms appear?
A 2024 medRxiv preprint by Almarri and colleagues (not yet peer-reviewed) explored exactly that.
They studied symptom-free adults, first a small group of 39, then 151 more in Nanjing, China, measuring immune cells called monocytes (part of the body’s defense team) and how often they clump with platelets.
The readings became a new score, MARS, which tracked real artery damage far more closely than the standard risk calculators doctors use now.
Early research, but a real hint that a blood sample may reveal what checklists miss.”
Other posts featuring Dima Shulkin on Hemostasis Today.
-
Aug 31, 2026, 14:03Adil Aftab: Anticoagulation in CKD – Key Updates from the 2026 ESC Guidelines
-
Aug 31, 2026, 14:01Isa Oboirien: Why Might Factor XI Inhibition Work Differently in Stroke and ACS?
-
Aug 31, 2026, 13:55Mike Morrissey: Advancing Europe’s Cardiovascular Health Agenda at ESC Congress 2026
-
Aug 31, 2026, 13:44Penilla Gunther: Patient Voices Take Center Stage in Cardiovascular Prevention at ESC Congress 2026
-
Aug 31, 2026, 13:42Mohamed Saleh Gomaa: Master the Latest in PE Management
-
Aug 31, 2026, 13:38Lyn Kleinbach-Reilly: A New Standard for Coagulation Testing in Neonatal Care
-
Aug 31, 2026, 13:36Rafael Gomes: Can Prasugrel Replace Ticagrelor in ACS Treatment?
-
Aug 31, 2026, 05:35Does LDL Cholesterol Influence VTE Risk? – Ordo Fraterna Fibonacci
-
Aug 31, 2026, 05:19Tania Ahuja: Apixaban in Abdominal Transplant Patients